Anticoagulants: Heparin, Warfarin, DOACs and Reversal Safety in 2026

Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Anticoagulants prevent or treat fibrin-rich thrombosis, including atrial fibrillation–associated embolism and venous thromboembolism. They do not directly dissolve established clots. Choice considers indication, renal/hepatic function, pregnancy, mechanical valves, bleeding risk and drug interactions [1, 2]. Classes…

Read Full News

Cardiac Glycosides and Inotropes: Digoxin, Dobutamine, Milrinone and Safety

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Cardiac glycosides and parenteral inotropes increase cardiac contractility through different mechanisms. They are not foundational mortality-reducing treatment for most patients with chronic heart failure with reduced ejection fraction (HFrEF): evidence-based neurohormonal therapies remain essential. Digoxin has selected…

Read Full News

Antihypertensive Drugs: 2025 AHA/ACC Guideline, Mechanisms and Safe Treatment

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Hypertension increases the risk of stroke, myocardial infarction, heart failure, kidney disease and premature death. The 2025 AHA/ACC guideline emphasizes repeated accurate blood pressure assessment, lifestyle interventions and individualized drug treatment. Home readings improve monitoring, but confirmation…

Read Full News

Beta Blockers in Cardiovascular Disease: Receptor Selectivity, HFrEF Evidence and Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Beta-adrenoceptor antagonists reduce catecholamine effects on cardiac rate, contractility, conduction and renin release. Benefits vary by indication and individual agent: beta blockade is not uniformly proven to reduce mortality in every patient with…

Read Full News

ACE Inhibitors: Clinical Pharmacology, CKD Benefits, Monitoring and Contraindications

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Angiotensin-converting enzyme (ACE) inhibitors decrease formation of angiotensin II and increase bradykinin, promoting vasodilation and reducing aldosterone secretion. Indications include hypertension, selected heart-failure regimens, post-MI LV dysfunction and albuminuric CKD. Medication choice should…

Read Full News